Micafungin Accord

Micafungin, the active ingredient in Micafungin Accord, is an echinocandin presented as an intravenous solution for intravenous use. It is employed to treat invasive candidiasis, esophageal candidiasis, Candida peritonitis, intra‑abdominal infections, and to provide prophylaxis for Candida infections in patients undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin Accord is an echinocandin antifungal used for serious Candida infections and prophylaxis in high‑risk patients.

- Invasive candidiasis: eradicates bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: clears mucosal infection of the esophagus. - Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infection during immune suppression. - Candida peritonitis and intra‑abdominal infections: treats intra‑abdominal Candida contamination.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate upset stomach. - Headache: occasional throbbing pain. - Elevated liver enzymes: transient increase in ALT/AST. - Infusion‑related reactions: flushing, chills, or mild hypotension. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Hepatic failure: significant liver injury requiring monitoring. - Anaphylaxis: severe allergic reaction with airway compromise. - Renal impairment: acute kidney injury in susceptible patients. - Severe hypotension: marked drop in blood pressure during infusion. - Stevens‑Johnson syndrome: severe mucocutaneous reaction. - Neutropenia: marked reduction in neutrophil count.

Before initiating Micafungin therapy, clinicians should assess patient‑specific risk factors and monitor organ function.

- Renal function monitoring: check serum creatinine and eGFR regularly. - Hepatic function monitoring: assess ALT, AST, bilirubin before and during treatment. - Concomitant hepatotoxic drugs: avoid or use with caution when combined with other liver‑affecting agents. - Known hypersensitivity: discontinue if allergic reaction occurs. - Pregnancy and lactation: use only if benefit outweighs potential risk, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with several agents, altering drug exposure or toxicity.

Major Interactions (Avoid): - Cyclosporine: micafungin may increase cyclosporine concentrations, risking nephrotoxicity. - Tacrolimus: co‑administration can raise tacrolimus levels, requiring dose adjustment.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce micafungin exposure, potentially compromising efficacy. - Fluconazole: may increase micafungin levels, warranting clinical monitoring. - Warfarin: possible alteration of INR; monitor coagulation parameters.